Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study

Trial Profile

Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bendamustine; Cyclophosphamide; Etoposide; Melphalan
  • Indications Hodgkin's disease; Lymphoma; Sezary syndrome; T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 20 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top